Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics

被引：6
|
作者：
Wang, Yunxia [1 ]
Liu, Xiaolin [1 ]
Gong, Luyao [1 ]
Ding, Weihong [2 ]
Hao, Wenjing [1 ]
Peng, Yeheng [1 ]
Zhang, Jun [1 ]
Cai, Weimin [1 ]
Gao, Yuan [1 ]
机构：
[1] Fudan Univ, Sch Pharm, Shanghai, Peoples R China
[2] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 2023年 / 180卷 / 23期
基金：
中国国家自然科学基金;
关键词：
biomarkers; drug resistance; renal cell carcinoma; sunitinib; treatment strategies; CONCISE GUIDE; MULTIDRUG-RESISTANCE; KINASE INHIBITORS; TUMOR PROGRESSION; EXPRESSION; PROTEIN; CANCER; POLYMORPHISMS; EFFICACY; THERAPY;
D O I：
10.1111/bph.16252
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Sunitinib is the first-line drug for renal cell carcinoma (RCC) treatment. However, patients who received sunitinib treatment will ultimately develop drug resistance after 6-15 months, creating a huge obstacle to the current treatment of renal cell carcinoma. Therefore, it is urgent to clarify the mechanisms of sunitinib resistance and develop new strategies to overcome it. In this review, the mechanisms of sunitinib resistance in renal cell carcinoma have been summarized based on five topics: activation of bypass or alternative pathway, inadequate drug accumulation, tumour microenvironment, metabolic reprogramming and epigenetic regulation. Furthermore, present and potential biomarkers, as well as potential treatment strategies for overcoming sunitinib resistance in renal cell carcinoma, are also covered.
引用
收藏
页码：2937 / 2955
页数：19
相关论文
共 50 条
  • [41] Targeting ferroptosis in renal cell carcinoma: Potential mechanisms and novel therapeutics
    Yang, Lei
    Fan, Yu
    Zhang, Qian
    HELIYON, 2023, 9 (08)
  • [42] AN ANALYSIS OF RENAL CELL CARCINOMA (RCC) XENOGRAFT MODELS DEVELOPING RESISTANCE TO SUNITINIB
    Noboru, S.
    Tomomi, K.
    Toshinari, Y.
    Toru, K.
    Ryuichiro, A.
    Hiromasa, S.
    Takahiro, I
    Osamu, O.
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 : 373 - 373
  • [43] Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
    L Zhou
    X-D Liu
    M Sun
    X Zhang
    P German
    S Bai
    Z Ding
    N Tannir
    C G Wood
    S F Matin
    J A Karam
    P Tamboli
    K Sircar
    P Rao
    E B Rankin
    D A Laird
    A G Hoang
    C L Walker
    A J Giaccia
    E Jonasch
    Oncogene, 2016, 35 : 2687 - 2697
  • [44] Tumor cell dedifferentiation into endothelial cells and resistance to sunitinib in renal carcinoma models
    Serova, Maria
    Tijeras-Raballand, Annemilai
    Dos Santos, Celia
    Riveiro, Maria Eugenia
    de Gramont, Armand
    Faivre, Sandrine
    Raymond, Eric
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [45] Nomogram for Predicting Resistance to Sunitinib in Patients with Metastatic Clear Cell Renal Carcinoma
    Kammerer-Jacquet, S-F
    Belaud-Rotureau, M-A
    Oger, E.
    Verhoest, G.
    Lespagnol, A.
    Edeline, J.
    Jaillard, S.
    Laguerre, B.
    Vauleon, E.
    Mosser, J.
    Bensalah, K.
    Rioux-Leclercq, N.
    LABORATORY INVESTIGATION, 2014, 94 : 238A - 238A
  • [46] Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
    Zhou, L.
    Liu, X-D
    Sun, M.
    Zhang, X.
    German, P.
    Bai, S.
    Ding, Z.
    Tannir, N.
    Wood, C. G.
    Matin, S. F.
    Karam, J. A.
    Tamboli, P.
    Sircar, K.
    Rao, P.
    Rankin, E. B.
    Laird, D. A.
    Hoang, A. G.
    Walker, C. L.
    Giaccia, A. J.
    Jonasch, E.
    ONCOGENE, 2016, 35 (21) : 2687 - 2697
  • [47] Nomogram for Predicting Resistance to Sunitinib in Patients with Metastatic Clear Cell Renal Carcinoma
    Kammerer-Jacquet, S-F
    Belaud-Rotureau, M-A
    Oger, E.
    Verhoest, G.
    Lespagnol, A.
    Edeline, J.
    Jaillard, S.
    Laguerre, B.
    Vauleon, E.
    Mosser, J.
    Bensalah, K.
    Rioux-Leclercq, N.
    MODERN PATHOLOGY, 2014, 27 : 238A - 238A
  • [48] Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma
    Hoshino, Yoshinori
    Hasegawa, Hirotoshi
    Ishii, Yoshiyuki
    Endo, Takashi
    Ochiai, Hiroki
    Okabayashi, Koji
    Kaneko, Gou
    Mikami, Shuji
    Mukai, Makio
    Oya, Mototsugu
    Kitagawa, Yuko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (04) : 412 - 416
  • [49] Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
    Schwandt, Anita
    Wood, Laura S.
    Rini, Brian
    Dreicer, Robert
    ONCOTARGETS AND THERAPY, 2009, 2 : 51 - 61
  • [50] Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma
    Teresa Bourlon, Maria
    Gao, Dexiang
    Trigero, Sara
    Elizabeth Clemons, Julia
    Lam, Elaine Tat
    Flaig, Thomas W.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345